Trial
NCT02387125
Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1
Phase ITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Collaborators
—
Condition
Sarcoma
Intervention
CMB305
Why stopped
This study did not meet the efficacy objective
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-07-01